INTRODUCTION
============

Sevoflurane is a fluorinated hydrocarbon that stands out among today's inhaled anesthetics due to its low solubility (blood: gas partition coefficient of 0.68), non-irritating effects on the respiratory tract and pleasant smell. These properties allow for rapid and smooth anesthesia induction even without pre-medication and offer good control over the depth of anesthesia, a factor that is important in patients with compromised hemodynamic status.[@b1-cln_65p531]

Depending on storage and usage conditions, sevoflurane can be degraded into different compounds, including the highly pungent hydrofluoric acid, a substance known to be nephrotoxic and irritating to the respiratory tract mucous membrane. This sevoflurane decomposition reaction involves a metallic impurity, an acid (a Lewis acid) and a substance capable of receiving an electron pair to trigger the decomposition reaction. A number of compounds, both organic and inorganic, including H~2~O, butylated hydroxytoluene, methylparaben, propylparaben, propofol and thymol, can inhibit the Lewis acid reaction. A liquid additive (water) was developed as a stabilizer to the original sevoflurane (Sevorane®, Abbott) to prevent the production of the inorganic fluorides. Cristália Laboratories developed a new sevoflurane formula (Sevocris®, Cristalia, São Paulo) containing 0.026% p/p of propylene glycol as a stabilizer.[@b2-cln_65p531] This new product was introduced into the Brazilian market in September 2004, after being granted the approval of ANVISA, Brazil's Regulatory Agency. Propylene glycol is a product utilized in several medications, via different routes, and has been considered a GRAS product (Generally Recognized as Safe) by the US Food and Drug Administration.[@b3-cln_65p531] It can be used as an antimicrobial preservative, disinfectant, humectant, solvent, vitamin stabilizer and water-miscible co-solvent.

Given this information, we conducted a comparative study of sevoflurane with water additive versus with propylene glycol additive under experimental conditions in pigs. We compared the MAC, hemodynamic and metabolic effects and relevant lung histopathological analyses.

MATERIALS AND METHODS
=====================

The study protocol and design were approved by the Ethics and Animal Investigation Committee at our institution and were performed according to the recommendations of the National Institutes of Health guidelines for ethical animal research. Sixteen young male Large White x Landrace pigs weighing 30 to 35 Kg (31.6±1.8 Kg) were fasted overnight with free access to water and were randomly assigned to the Sevo A or Sevocris groups. After induction of anesthesia via mask with the assigned sevoflurane (6% in 100% oxygen), animals were orally intubated (7 mm internal diameter cuffed endotracheal tube, Hi-Lo, National Catheter, Argyle, NY). The lungs were mechanically ventilated (Primus, Dräger Medical, Lubeck, Germany) using volume-controlled ventilation, 40% FiO~2~, tidal volume of 8 mL/kg, PEEP of 5 cm H~2~O, which was the respiratory frequency adjusted to keep end-tidal CO~2~ between 35 and 45 mmHg. Anesthesia was maintained with 5% sevoflurane in 40% oxygen.

A continuous infusion of lactated Ringer (Baxter, São Paulo, Brazil) was provided at a rate of 5 mL.kg^−1^.h^−1^ throughout all experiments. The temperature was maintained within normal limits for pigs (38.7--39.9°C) using warm blankets (Medi-therm II, Gaymar Industries, Orchard Park, NY, USA).

Instrumentation
---------------

After local anesthetic infiltration (10 mL 2% lidocaine with vasoconstrictor), the right femoral artery was surgically exposed and catheterized for arterial pressure measurements and blood collection. The right jugular vein was also catheterized with a pulmonary artery catheter (7.5 F Edwards CCO catheter connected to Edwards Vigilance CCO Monitor; Edwards Lifesciences Corp., Irvine, CA, USA). The position of the pulmonary artery catheter was confirmed by typical waveforms. All intravascular catheters were zeroed to atmospheric pressure. The midpoint between the anterior and posterior chest walls was taken as the zero reference point for pressure measurements.

The STAT-Mode of the Edwards Vigilance CCO Monitor was used in each experiment, which displayed the actual cardiac output values registered over the past 60 seconds. The last five measurements of CO were averaged. The electrocardiogram and intravascular pressures, mean arterial pressure (MAP), mean pulmonary artery pressure (MPAP), pulmonary artery wedge pressure (PAWP) and central venous pressure (CVP) were monitored continuously (MP40, Philips). Numerical values of intravascular pressures from the monitor screen were recorded at established points of the protocol. After instrumentation, animals were allowed to stabilize for 60 minutes.

Hemodynamic indices
-------------------

The derivative indexes were recorded directly from monitors during the experiment: the pulmonary vascular resistance index (PVRI), systemic vascular resistance index (SVRI), right and left ventricular stroke work index (RVSWI and LVSWI), right stroke volume index, (RSVI), right ventricle ejection fraction (RVEF) and right ventricular end-diastolic volume (RVEDV). The cardiac index (CI) was calculated according to calculated body surface (k.BW^2/3^, where k = 0.09, BW=body weight).[@b4-cln_65p531], [@b5-cln_65p531]

Venous admixture and oxygenation indices
----------------------------------------

Arterial and mixed venous blood samples were collected for pH, partial pressure of arterial oxygen (PaO~2~), partial pressure of arterial carbon dioxide (PaCO~2~), arterial oxygen saturation (SaO~2~), partial pressure of mixed venous oxygen (PvO~2~) and mixed venous saturation (SvO~2~) (ABL 555; Radiometer, Copenhagen, Denmark). The oxygen delivery index (DO~2~I), oxygen consumption index (VO~2~I) and extraction ratio (O~2~ER) were calculated utilizing conventional formulas.

Determination of MAC
--------------------

The method for the determination of MAC in this study has been described elsewhere.[@b6-cln_65p531],[@b7-cln_65p531]

The end-tidal concentration of sevoflurane was maintained at the intended level for a 15 min equilibration period. After 15 min of equilibration, the pig was stimulated on a dew claw with a hemostat clamped to a full ratchet lock for 60 s. The leg was moved back and forth. If there were no purposeful movements in response to the stimulus (withdrawal of the clamped foot or gross movements of either legs or head), the end-tidal sevoflurane was decreased by 10%, and the protocol was repeated following a 15 min anesthetic equilibration period. If there was purposeful movement in response to the stimulation, the end-tidal concentration was increased by 5%, and following equilibration, the stimulation was repeated. The site of the stimulations was changed slightly to prevent sensitization or desensitization to subsequent stimuli. The expiratory concentration of the agent halfway between that allowing and that not allowing movement in response was the MAC of that agent for each specific animal.

After MAC determination, systemic hemodynamics, respiratory data and blood gases were collected at 0.5, 1.0 and 1.5 MAC, observing a 15 min equilibrium period after each concentration change.

Histopathological analysis
--------------------------

At the end of the experiment, while still under anesthesia, animals received a 1-g bolus of thiopental followed by 25 mEq of potassium chloride. Lung samples were collected from the left diaphragmatic lobe (from zones 1, 2 and 3). A sample from the middle portion of the trachea was also collected. The lung and trachea samples were prepared for optical analyses, fixed in 10% formaldehyde and stained with hematoxylin and eosin.

The pathologist, who was blinded to the experimental protocol, described the analysis according to the combined assessment of neutrophils, eosinophils, mastocytes, and mononuclear cell accumulation, pulmonary interstitial edema, alveoli collapse, and congestion in the prepared sample lamina using an optical microscope at a magnification of 10x. In a subjective manner, the observer quantified the positive findings in the samples from different regions of the lung as none (0), discrete (1), moderate (2), or intense (3).

Statistical analysis
--------------------

MAC values were analyzed using the Student's *t*-test. Hemodynamic and other parametric data were analyzed within groups and between groups using an analysis of variance (ANOVA) for repeated measurements with two factors (SigmaStat 3.11, Systat Software Inc, San Jose, USA). When appropriate, post hoc analyses were performed with the Tukey test. P\<0.05 was considered statistically significant. Values are presented as means (SD).

RESULTS
=======

The MAC for the Sevo A group was 4.4% (0.5), whereas it was 4.1% (0.7) for the Sevocris group. Body weights, MAC values and times to achieve sternal recumbence and to orotracheal intubation are presented in [Table 1](#t1-cln_65p531){ref-type="table"}.

Hemodynamic, respiratory and oxygenation parameters are described in [Tables 2](#t2-cln_65p531){ref-type="table"} and [3](#t3-cln_65p531){ref-type="table"}.

Hemodynamic parameters presented significant differences in a dose-dependent pattern as expected, but did not differ between groups. Cardiac indices decreased significantly in both groups when the sevoflurane concentration increased from 0.5 to 1 and 1.5 MAC. We also observed a significant decrease in blood pressure and mean pulmonary artery pressure at all concentrations compared to 0.5 MAC. Heart rate decreased significantly when MAC was augmented from 0.5 to 1.0 and 1.5, but the values remained in the physiological range for this group of animals, and bradycardia was not verified. SvO~2~ and DO~2~I decreased significantly at 1.5 MAC when compared to 0.5 and 1.0 MAC.

Regarding histopathological analyses, no evidence of neutrophils, eosinophils, mastocytes, mononuclear cell accumulation, pulmonary interstitial edema, alveoli collapse, or congestion was found in lung optical microscopy of both groups. Also, no histopathological changes were found in the trachea.

DISCUSSION
==========

The main finding in this study was that hemodynamic and metabolic responses at equipotent doses were similar between water-added sevoflurane (Sevo A) and propylene glycol-added sevoflurane (Sevocris).

Under the conditions of this study, the MAC of Sevo A was 4.4% (0.5), and the MAC of Sevocris was 4.1% (0.7). These values are higher than most published reports, in which sevoflurane MAC values range between 2.1% and 4.4% in pigs.[@b8-cln_65p531]--[@b13-cln_65p531]

Several factors may account for the variations in published sevoflurane MAC values, including different age groups of pigs, body temperature, pre-anesthetic and induction agents, the type and site of noxious stimulus and the defined end-point for determination of purposeful movement in response to the applied stimulus ([Table 4](#t4-cln_65p531){ref-type="table"}). [@b6-cln_65p531], [@b7-cln_65p531], [@b14-cln_65p531] The stimulus applied in our study was dewclaw clamping, which has been reported to be a supramaximal stimulus[@b6-cln_65p531] and which remained constant during the entire study. The site of stimulus was changed slightly between stimulations to prevent sensitization or desensitization to subsequent stimuli. In the study of Hecker,[@b10-cln_65p531] where the pigs had almost the same weight and were submitted to the same nociceptive stimulation as in the present study, the MAC was lower, which may have been due to the previous use of azaperone and propofol. Holmström and Åkeson,[@b13-cln_65p531] in animals weighing 20.1± 0.7 kg, obtained a MAC of 4.4 90 minutes after propofol administration, which is the same value reported in the present investigation. On the other hand, Moeser et al.,[@b12-cln_65p531] studying animals weighing 19 ±0.4 kg and with no other agent than sevoflurane, obtained a MAC of 3.5±0.17. In the present investigation, weight, age, sex, and stimuli were similar in both groups, demonstrating that the two anesthetics showed the same behavior with regard to MAC.

The hemodynamic results are close to those described in the literature for sevoflurane. In healthy human volunteers and in dogs, the cardiac index, arterial pressure and pulmonary arterial pressure decrease in a dose-dependent manner.[@b15-cln_65p531],[@b16-cln_65p531] In infants, sevoflurane did not alter the cardiac index at any concentration compared to awake values but significantly decreased blood pressure and systemic vascular resistance compared to awake values at all concentrations.[@b17-cln_65p531]

Special focus has been given to the effects of volatile anesthetics on heart rate because desflurane (and to a lesser extent isoflurane) can initiate major increases in heart rate that might predispose select patient populations to myocardial ischemia.[@b18-cln_65p531] The results with sevoflurane are conflicting, varying across different species, age groups and anesthetic techniques. Sevoflurane has not been associated with increases in heart rate in healthy volunteers, in patients,[@b19-cln_65p531] or in children.[@b17-cln_65p531] Bernard et al.,[@b16-cln_65p531] in dogs, noted significant increases in heart rate from the awake state during the administration of 1.2--2.0 MAC. In the present study, heart rate decreased when the MAC was augmented from 0.5 to 1.0 and 1.5, but the values obtained remained in the physiological range for this group of animals, and bradycardia was not verified.

The effects of both tested sevofluranes on cardiac performance (LVSWI, RVSWI, SVI and EDVI) were the same and are in accordance with the literature. The influence of sevoflurane on performance of the right ventricle (RV) was studied by Kerbaul and colleagues, who observed a significant decrease in the RV stroke work with 1 and 1.5 MAC of sevoflurane. ~20~

Ventilation was kept constant in order to maintain the levels of carbon dioxide, which may influence cardiovascular function. The decreases in the oxygenation parameters, verified with the increases in MAC, may be associated with cardiovascular depression. The changes were more pronounced when MAC was raised to 1.5, contributing to a significant decrease in SvO~2~ and PvO~2~, while the oxygen extraction rate increased. Lactate remained unchanged with 1.0 MAC and increased slightly with 1.5.

No lung histopathological changes were associated with the two compositions of sevoflurane tested. The literature describes how sevoflurane may be degraded by metallic substances resulting in fluoridric acid, which may cause damage to the respiratory tract mucous membrane when inhaled, and many other fluoride-degrading products. To inhibit acid formation, substances such as water and, more recently, propylene glycol have been added to sevoflurane. A test conducted with a sevoflurane sample with 260 ppm of propylene glycol, heated to a temperature above 60°C in the presence of alumina, did not show significant change in the content of individual and total impurities when compared to those of the dry sevoflurane. The fluoride content of this sample was 0.051 μg/mL, which complied with specifications set by the USP Pharmacopoeia Forum, which determines a maximum fluoride limit of 2 μg/mL.[@b2-cln_65p531]

The exact mechanism through which propylene glycol stabilizes sevoflurane is not entirely clear, but it is possible to infer that propylene glycol and the Lewis acid form a compound that is highly efficient for blocking the action of metallic impurities on sevoflurane.

With regard to the possible toxicological effects of propylene glycol, hyperosmolality lactic acidosis, a central nervous system dysfunction, and cardiovascular disturbances were observed in patients receiving etomidate in a 35% propylene glycol vehicle.[@b21-cln_65p531], [@b22-cln_65p531] In the present investigation, the sevoflurane contained 0.026% of propylene glycol, which is far less than the amount contained in etomidate formulation.

Moreover, after a study conducted by Bau et al. in which propylene glycol was a constituent of an aerosol formulation, the authors concluded that, under normal conditions of exposure, propylene glycol via inhalation is of limited toxicological relevance.[@b23-cln_65p531]

In conclusion, propylene glycol as a sevoflurane additive can be used as safely as water as an additive, at least in terms of hemodynamic and pulmonary effects.

###### 

Body weight, MAC, time to sternal recumbency and orotracheal intubation.

                               Sevo A       Sevocris
  ---------------------------- ------------ ------------
  Body weight (kg)             31.3 (1.9)   31.9 (1.9)
  MAC (%)                      4.4 (0.5)    4.1 (0.7)
  Sternal recumbency (s)       116 (96)     112 (36)
  Orotracheal intubation (s)   659 (433)    620 (275)

Mean (SD)

###### 

Hemodynamic data.

                                Group      0.5 MAC                                                 1.0 MAC      1.5 MAC
  ----------------------------- ---------- ------------------------------------------------------- ------------ -------------------------------------------------------------------------------------------------
  CI (L/min/m^2^)               Sevo A     5.5 (1.3) [\*](#tfn3-cln_65p531){ref-type="table-fn"}   4.2 (0.8)    3.2 (1.0) [\*](#tfn3-cln_65p531){ref-type="table-fn"}[†](#tfn4-cln_65p531){ref-type="table-fn"}
                                Sevocris   6.2 (0.7) [\*](#tfn3-cln_65p531){ref-type="table-fn"}   4.7 (1.1)    3.6 (1.2) [\*](#tfn3-cln_65p531){ref-type="table-fn"}[†](#tfn4-cln_65p531){ref-type="table-fn"}
  HR (beat/min)                 Sevo A     129 (20)                                                122 (17)     110 (16) [\*](#tfn3-cln_65p531){ref-type="table-fn"}[†](#tfn4-cln_65p531){ref-type="table-fn"}
                                Sevocris   138 (19) [\*](#tfn3-cln_65p531){ref-type="table-fn"}    115 (15)     104 (13) [†](#tfn4-cln_65p531){ref-type="table-fn"}
  MAP (mmHg)                    Sevo A     81 (15) [\*](#tfn3-cln_65p531){ref-type="table-fn"}     66 (7)       45 (10) [\*](#tfn3-cln_65p531){ref-type="table-fn"}[†](#tfn4-cln_65p531){ref-type="table-fn"}
                                Sevocris   90 (17) [\*](#tfn3-cln_65p531){ref-type="table-fn"}     68 (10)      52 (11) [\*](#tfn3-cln_65p531){ref-type="table-fn"}[†](#tfn4-cln_65p531){ref-type="table-fn"}
  CVP (mmHg)                    Sevo A     8 (2)                                                   9 (2)        9 (2)
                                Sevocris   7 (2) [\*](#tfn3-cln_65p531){ref-type="table-fn"}       9 (1)        10 (1) [†](#tfn4-cln_65p531){ref-type="table-fn"}
  MPAP (mmHg)                   Sevo A     23 (3) [\*](#tfn3-cln_65p531){ref-type="table-fn"}      21 (2)       19 (3) [\*](#tfn3-cln_65p531){ref-type="table-fn"}[†](#tfn4-cln_65p531){ref-type="table-fn"}
                                Sevocris   22 (3) [\*](#tfn3-cln_65p531){ref-type="table-fn"}      21 (3)       20 (3) [†](#tfn4-cln_65p531){ref-type="table-fn"}
  PAWP (mmHg)                   Sevo A     11 (2)                                                  12 (2)       12 (1)
                                Sevocris   11 (1)                                                  11 (1)       12 (2)
  SVRI (dynes.sec/cm^5^/m^2^)   Sevo A     1076 (211)                                              1106 (185)   896 (201) [\*](#tfn3-cln_65p531){ref-type="table-fn"}[†](#tfn4-cln_65p531){ref-type="table-fn"}
                                Sevocris   1080 (201)                                              1047 (260)   959 (193)
  PVRI (dynes.sec/cm^5^/m^2^)   Sevo A     171 (34)                                                183 (30)     187 (61)
                                Sevocris   153 (35)                                                165 (41)     184 (63)
  LVSWI (gm-m/m^2^/beat)        Sevo A     41 (12) [\*](#tfn3-cln_65p531){ref-type="table-fn"}     26 (6)       13 (6) [\*](#tfn3-cln_65p531){ref-type="table-fn"}[†](#tfn4-cln_65p531){ref-type="table-fn"}
                                Sevocris   47 (13) [\*](#tfn3-cln_65p531){ref-type="table-fn"}     33 (6)       20 (9) [\*](#tfn3-cln_65p531){ref-type="table-fn"}[†](#tfn4-cln_65p531){ref-type="table-fn"}
  RVSWI (gm-m/m^2^/beat)        Sevo A     8 (2) [\*](#tfn3-cln_65p531){ref-type="table-fn"}       6 (1)        4 (2) [\*](#tfn3-cln_65p531){ref-type="table-fn"}[†](#tfn4-cln_65p531){ref-type="table-fn"}
                                Sevocris   9 (1) [\*](#tfn3-cln_65p531){ref-type="table-fn"}       7 (2)        5 (2) [\*](#tfn3-cln_65p531){ref-type="table-fn"}[†](#tfn4-cln_65p531){ref-type="table-fn"}
  SVI (mL/m^2^/beat)            Sevo A     44 (9) [\*](#tfn3-cln_65p531){ref-type="table-fn"}      34 (5)       28 (6) [\*](#tfn3-cln_65p531){ref-type="table-fn"}[†](#tfn4-cln_65p531){ref-type="table-fn"}
                                Sevocris   45 (6)                                                  41 (8)       34 (9) [\*](#tfn3-cln_65p531){ref-type="table-fn"}[†](#tfn4-cln_65p531){ref-type="table-fn"}
  EDVI (mL/m^2^)                Sevo A     159 (33)                                                157 (52)     156 (58)
                                Sevocris   162 (30)                                                148 (19)     146 (11)

Mean (SD); CI=cardiac index; HR=heart rate; MAP=mean arterial pressure; CVP=central venous pressure; MPAP=mean pulmonary artery pressure; PCWP=pulmonary artery wedge pressure; SVRI=systemic vascular resistance index; PVRI=pulmonary vascular resistance index; LVSWI=left ventricular stroke work index; RVSWI=right ventricular stroke work index; SVI=stroke volume index; EDVI=right ventricular end-diastolic volume index.

P\<0.05 compared to 1 MAC;

P\<0.05 compared to 0.5 MAC.

###### 

Respiratory and oxygenation data.

                            Group      0.5 MAC                                                 1.0 MAC         1.5 MAC
  ------------------------- ---------- ------------------------------------------------------- --------------- ---------------------------------------------------------------------------------------------------
  RR (mpm)                  Sevo A     19 (2)                                                  19 (2)          19 (2)
                            Sevocris   20 (2)                                                  20 (2)          20 (2)
  P Peak (cmH~2~O)          Sevo A     22 (3)                                                  21 (3)          21 (3)
                            Sevocris   20 (4)                                                  20 (3)          20 (3)
  P Plato (cmH~2~O)         Sevo A     20 (3)                                                  20 (3)          20 (3)
                            Sevocris   19 (3)                                                  19 (3)          19 (3)
  Compl~Dyn~ (mL/cmH~2~O)   Sevo A     23 (5) [\*](#tfn6-cln_65p531){ref-type="table-fn"}      26 (6)          27 (6) [†](#tfn7-cln_65p531){ref-type="table-fn"}
                            Sevocris   24 (5)                                                  26 (4)          26 (5)
  Vt (mL)                   Sevo A     339 (22) [\*](#tfn6-cln_65p531){ref-type="table-fn"}    359 (29)        370 (39) [\*](#tfn6-cln_65p531){ref-type="table-fn"}[†](#tfn7-cln_65p531){ref-type="table-fn"}
                            Sevocris   335 (22) [\*](#tfn6-cln_65p531){ref-type="table-fn"}    350 (28)        362 (22) [\*](#tfn6-cln_65p531){ref-type="table-fn"}[†](#tfn7-cln_65p531){ref-type="table-fn"}
  EtCO~2~ (mmHg)            Sevo A     44 (2)                                                  43 (2)          41 (2) [\*](#tfn6-cln_65p531){ref-type="table-fn"}[†](#tfn7-cln_65p531){ref-type="table-fn"}
                            Sevocris   44 (2)                                                  43 (4)          41 (4) [†](#tfn7-cln_65p531){ref-type="table-fn"}
  pH art                    Sevo A     7.454 (0.024)                                           7.463 (0.026)   7.477 (0.025)
                            Sevocris   7.464 (0.024)                                           7.472 (0.041)   7.459 (0.060)
  PaCO~2~ (mmHg)            Sevo A     45 (2)                                                  44 (3)          40 (5)
                            Sevocris   44 (2)                                                  43 (5)          42 (8)
  PaO~2~ (mmHg)             Sevo A     174 (36)                                                166 (40)        160 (43)
                            Sevocris   181 (20)                                                162 (27)        157 (33)
  SaO~2~ (%)                Sevo A     99.2 (0.5)                                              99.0 (0.5)      98.9 (0.9)
                            Sevocris   99.4 (0.2)                                              99.1 (0.4)      99.0 (0.7) [†](#tfn7-cln_65p531){ref-type="table-fn"}
  Lactate (mmol/L)          Sevo A     1.1 (0.3)                                               1.1 (0.3)       1.5 (1.0)
                            Sevocris   1.0 (0.2)                                               1.1 (0.3)       1.3 (0.3)
  PvO~2~ (mmHg)             Sevo A     47 (5)                                                  45 (6)          36 (5) [\*](#tfn6-cln_65p531){ref-type="table-fn"}[†](#tfn7-cln_65p531){ref-type="table-fn"}
                            Sevocris   50 (3) [\*](#tfn6-cln_65p531){ref-type="table-fn"}      45 (5)          38 (6) [\*](#tfn6-cln_65p531){ref-type="table-fn"}[†](#tfn7-cln_65p531){ref-type="table-fn"}
  SvO~2~ (%)                Sevo A     77.3 (7.3)                                              76.1 (7.3)      62.5 (14.7) [\*](#tfn6-cln_65p531){ref-type="table-fn"}[†](#tfn7-cln_65p531){ref-type="table-fn"}
                            Sevocris   81.6 (3.9)                                              76.0 (6.2)      64.7 (12.4) [\*](#tfn6-cln_65p531){ref-type="table-fn"}[†](#tfn7-cln_65p531){ref-type="table-fn"}
  DO~2~I (mL/min/m^2^)      Sevo A     825 (172) [\*](#tfn6-cln_65p531){ref-type="table-fn"}   606 (56)        434 (96) [\*](#tfn6-cln_65p531){ref-type="table-fn"}[†](#tfn7-cln_65p531){ref-type="table-fn"}
                            Sevocris   880 (66) [\*](#tfn6-cln_65p531){ref-type="table-fn"}    671 (176)       498 (156) [\*](#tfn6-cln_65p531){ref-type="table-fn"}[†](#tfn7-cln_65p531){ref-type="table-fn"}
  VO~2~I (mL/min/m^2^)      Sevo A     173 (19)                                                142 (33)        143 (31)
                            Sevocris   175 (22)                                                162 (32)        162 (12)
  O~2~ER (%)                Sevo A     23 (7)                                                  24 (6)          35 (12) [\*](#tfn6-cln_65p531){ref-type="table-fn"}[†](#tfn7-cln_65p531){ref-type="table-fn"}
                            Sevocris   20 (3)                                                  25 (6)          36 (13)[\*](#tfn6-cln_65p531){ref-type="table-fn"}[†](#tfn7-cln_65p531){ref-type="table-fn"}
  Temp (°C)                 Sevo A     38.3 (0.4)                                              38.4 (0.5)      38.5 (0.5)
                            Sevocris   38.6 (0.6)                                              38.6 (0.4)      38.7 (0.5)

Mean (SD); RR=respiratory rate; P peak=airway peak pressure; P plato=airway plato pressure; Compl~Dyn~=dynamic compliance; Vt=tidal volume; EtCO~2~=end-tidal CO~2~; pH art=arterial pH; PaCO~2~=partial pressure of arterial CO~2~; PaO~2~=partial pressure of arterial oxygen; SaO~2~=arterial oxygen saturation; Lactate=arterial lactate; PvO~2~=partial pressure of mixed venous oxygen; SvO~2~=mixed venous saturation; DO~2~I=oxygen delivery index; VO~2~I=oxygen consumption index; O~2~ER=oxygen extraction ratio; Temp=temperature.

P\<0.05 compared to 1 MAC;

P\<0.05 compared to 0.5 MAC.

###### 

MAC (means±SD) results and methods employed in previous studies of pigs on sevoflurane.

  Reference                                Age (weeks)   Weight (Kg)   Anesthesia protocol                          Nociceptive stimulation           Temperature (°C)   MAC (%)
  ---------------------------------------- ------------- ------------- -------------------------------------------- --------------------------------- ------------------ -----------
  Lerman et al.[@b8-cln_65p531]            newborn       2.1±0.4       mask induction                               hoof coronary ligament clamping   37.5--38.5         2.12±0.39
  Allaouchiche et al. [@b9-cln_65p531]     12--14        23±2          after ketamine and propofol                  dewclaw clamping                  38.6±0.6           2.4
  Hecker et al. [@b10-cln_65p531]          NS            30.8±2.6      3 h after azaperone, 45 min after propofol   dewclaw clamping                  38.1               2.53±0.47
  Manohar and Parks[@b11-cln_65p531]       22--25        58.7±1.8      mask induction                               tail clamping                     39.7±0.1           2.66±0.6
  Moeser et al. [@b12-cln_65p531]          9             19±4          mask induction                               dewclaw clamping                  38.1               3.5±0.17
  Holmström and Åkeson [@b13-cln_65p531]   NS            20.1±0.7      90 min after propofol                        dewclaw clamping                  38.0±0.2           4.4±0.1

NS=not stated.
